slow dissolution variant 2

Slow dissolution variant 2 is a specific oral formulation of AZD5069, a small molecule developed by AstraZeneca. This particular variant was investigated in a Phase 1 clinical study to assess its relative bioavailability in healthy volunteers, with a primary focus on its potential application in uncontrolled and persistent asthma. AZD5069 functions as a selective and reversible antagonist of the CXC chemokine receptor 2 (CXCR2). By binding to and inhibiting CXCR2, it reduces neutrophil recruitment and migration to sites of inflammation, such as the lung mucosa, and may also prevent neutrophil migration from the bone marrow. This mechanism contributes to its potential anti-inflammatory and antineoplastic activities, as CXCR2 plays a key role in inflammatory diseases and tumor cell proliferation.